z-logo
open-access-imgOpen Access
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
Author(s) -
Pascoal Tharick A.,
Therriault Joseph,
Mathotaarachchi Sulantha,
Kang Min Su,
Shin Monica,
Benedet Andrea L.,
Chamoun Mira,
Tissot Cecile,
Lussier Firoza,
Mohaddes Sara,
Soucy JeanPaul,
Massarweh Gassan,
Gauthier Serge,
RosaNeto Pedro
Publication year - 2020
Publication title -
alzheimer's and dementia: diagnosis, assessment and disease monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.497
H-Index - 37
ISSN - 2352-8729
DOI - 10.1002/dad2.12037
Subject(s) - dementia , positron emission tomography , abnormality , medicine , neuroimaging , standardized uptake value , psychology , voxel , pathology , neuroscience , psychiatry , radiology , disease
Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown whether the assessment of the topographical distribution of Aβ pathology can provide additional information to identify, among global Aβ positive individuals, those destined for dementia. Methods We studied 260 amnestic mild cognitive impairment (MCI) subjects who were Aβ‐PET positive with [ 18 F]florbetapir. Using [ 18 F]florbetapir, we assessed the percentage of voxels sowing Aβ abnormality as well as the standardized uptake value ratio (SUVR) values across brain regions. Regressions tested the predictive effect of Aβ on progression to dementia over 2 years. Results Neither global nor regional [ 18 F]florbetapir SUVR concentrations predicted progression to dementia. In contrast, the spatial extent of Aβ pathology in regions comprising the default mode network was highly associated with the development of dementia over 2 years. Discussion These results highlight that the regional distribution of Aβ abnormality may provide important complementary information at an individual level regarding the likelihood of Aβ positive MCI to progress to dementia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here